REGiMMUNE

REGiMMUNE presents enhanced efficacy data in preclinical transplantation models

RGI-2001 demonstrates enhanced efficacy in skin transplantation and acute Graft-versus-Host disease when combined with low-dose Sirolimus. The combination treatment prolongs graft survival and reduces GvHD mortality, indicating potential as a tolerance induction regimen.

SourceREGiMMUNE·DateJun 1, 2009

REGiMMUNE receives $12 million in grants to develop transplant and allergy drugs

REGiMMUNE receives significant funding from Japan's JST and NIBIO to advance its immunosuppressant ToleroVax for GvHD and allergy treatment reVax. The grants will support preclinical and clinical programs for these promising therapies.

SourceREGiMMUNE·DateDec 8, 2008